Pendientes aún en PharmaMar de la Entrada de 200 Million Dollars Cash . Está Cantidad está Sujeta a la correspondiente Autorización de las Autoridades de Antimonopolio de Estados Unidos (Hart Scott Rodino Act.).
Jazz Rolls the Dice on A Billion-Dollar Gamble on a New Drug for SCLC — Shooting for a 2020 Launchy .
December 19, 2019 .
Jazz is Handing off the Cash and Promising $800 Million more in a Billion-Dollar bet that the Drug can Carve a Straight Path from Positive Phase II data Right into the Lucrative Market for SMALL CELL LUNG CANCER — a tough Field for Drug Hunters. Out of the $800 Million, $250 Million is Reserved for Regulatory Approvals as they Steer the Drug to a Potential 2020 Launch. ...
SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .







